475 related articles for article (PubMed ID: 26781617)
1. Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.
Subari S; Baidoun F; Hreh M; Patnaik M; Hashmi S; Elliott M; Hogan W; Litzow M; Al-Kali A
Int J Hematol; 2016 Apr; 103(4):409-15. PubMed ID: 26781617
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
Cabrero M; Jabbour E; Ravandi F; Bohannan Z; Pierce S; Kantarjian HM; Garcia-Manero G
Leuk Res; 2015 May; 39(5):520-4. PubMed ID: 25828745
[TBL] [Abstract][Full Text] [Related]
3. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
[TBL] [Abstract][Full Text] [Related]
5. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.
Short NJ; Venugopal S; Qiao W; Kadia TM; Ravandi F; Macaron W; Dinardo CD; Daver N; Konopleva M; Borthakur G; Shpall EJ; Popat U; Champlin RE; Mehta R; Al-Atrash G; Oran B; Jabbour E; Garcia-Manero G; Issa GC; Montalban-Bravo G; Yilmaz M; Maiti A; Kantarjian H
J Hematol Oncol; 2022 Jan; 15(1):12. PubMed ID: 35093134
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Boddu PC; Kantarjian HM; Ravandi F; Garcia-Manero G; Verstovsek S; Jabbour EJ; Takahashi K; Bhalla K; Konopleva M; DiNardo CD; Ohanian M; Pemmaraju N; Jain N; Pierce S; Wierda WG; Cortes JE; Kadia TM
Cancer; 2017 Aug; 123(16):3050-3060. PubMed ID: 28387922
[TBL] [Abstract][Full Text] [Related]
7. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
[TBL] [Abstract][Full Text] [Related]
8. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
9. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
10. Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.
Vachhani P; Al Yacoub R; Miller A; Zhang F; Cronin TL; Ontiveros EP; Thompson JE; Griffiths EA; Wang ES
Leuk Res; 2018 Dec; 75():29-35. PubMed ID: 30445237
[TBL] [Abstract][Full Text] [Related]
11. Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies.
Pan T; Qi J; You T; Yang L; Wu D; Han Y; Zhu L
Leuk Res; 2018 Aug; 71():13-24. PubMed ID: 29936305
[TBL] [Abstract][Full Text] [Related]
12. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
Jabbour EJ; Garcia-Manero G; Strati P; Mishra A; Al Ali NH; Padron E; Lancet J; Kadia T; Daver N; O'Brien S; Steensma DP; Sekeres MA; Gore SD; Dezern A; Roboz GJ; List AF; Kantarjian HM; Komrokji RS
Cancer; 2015 Mar; 121(6):876-82. PubMed ID: 25410759
[TBL] [Abstract][Full Text] [Related]
13. Hypomethylating agents and chemotherapy in MDS.
Adès L; Santini V
Best Pract Res Clin Haematol; 2013 Dec; 26(4):411-9. PubMed ID: 24507817
[TBL] [Abstract][Full Text] [Related]
14. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
Ravandi F; Issa JP; Garcia-Manero G; O'Brien S; Pierce S; Shan J; Borthakur G; Verstovsek S; Faderl S; Cortes J; Kantarjian H
Cancer; 2009 Dec; 115(24):5746-51. PubMed ID: 19795507
[TBL] [Abstract][Full Text] [Related]
15. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
[TBL] [Abstract][Full Text] [Related]
16. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
Sekeres MA; Maciejewski JP; Erba HP; Afable M; Englehaupt R; Sobecks R; Advani A; Seel S; Chan J; Kalaycio ME
Cancer; 2011 Mar; 117(6):1253-61. PubMed ID: 20960521
[TBL] [Abstract][Full Text] [Related]
17. Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
Cabezón M; Malinverni R; Bargay J; Xicoy B; Marcé S; Garrido A; Tormo M; Arenillas L; Coll R; Borras J; Jiménez MJ; Hoyos M; Valcárcel D; Escoda L; Vall-Llovera F; Garcia A; Font LL; Rámila E; Buschbeck M; Zamora L;
Clin Epigenetics; 2021 Jan; 13(1):9. PubMed ID: 33446256
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Spagnoli A; Voso MT; Fianchi L; Papayannidis C; Gaidano GL; Breccia M; Musto P; De Bellis E; Del Principe MI; Lunghi M; Lessi F; Martinelli G; Venditti A
Ann Hematol; 2018 Oct; 97(10):1767-1774. PubMed ID: 29947973
[TBL] [Abstract][Full Text] [Related]
19. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
[TBL] [Abstract][Full Text] [Related]
20. Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy.
Talati C; Goldberg AD; Przespolewski A; Chan O; Ali NA; Kim J; Famulare C; Sallman D; Padron E; Kuykendall A; Lancet JE; Wang E; Tallman MS; Komrokji R; Sweet K
Leuk Res; 2020 Jun; 93():106367. PubMed ID: 32408060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
